Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by david50on Jun 12, 2009 12:47pm
542 Views
Post# 16066143

Merck payment to Ambrilia

Merck payment to AmbriliaLast  weeks news release stated the following ......go figure did Ambrila receive the payment or not?....why is Ambrilia not telling anyone if the payment arrived, in fairness Merck has until Monday to make the payment . The way Ambrilia is going I can see them on the TSX venture exchange by years end, or out of business imo

The settlement agreement also provides for the payment by Merck to Ambrilia of an amount of $2-million (U.S.) within 10 business days of the settlement and a royalty for a period of 10 years from first commercial sale of a certain family of products, and the release of all claims made in the arbitration.


Show me the money Ambrilia...lol

IMO Guess the AGM was canceled so the board can plan some vacations with the $2 million dollars thats coming out of Merck, but imo shareholders will never know if the money arrived on time.
Bullboard Posts